Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Novacyt ( (FR:ALNOV) ) just unveiled an announcement.
Novacyt has reported an 85% revenue growth for 2024, driven by the acquisition of Yourgene Health, bringing in significant contributions despite some revenue reductions in specific areas. The company has made notable progress in its Reproductive Health business and Ranger Technology consumables, aiming for further growth through product and operational enhancements. These strategic developments are expected to underpin Novacyt’s long-term growth and enhance its market position in the molecular diagnostics industry.
More about Novacyt
Novacyt is an international molecular diagnostics company offering a comprehensive range of integrated technologies and services, primarily focused on the delivery of genomic medicine. It develops, manufactures, and commercializes molecular assays and instrumentation to provide end-to-end solutions across sectors like human health, animal health, and the environment. The company operates through three segments: clinical diagnostics, including reproductive health and infectious diseases; instrumentation, featuring DNA sample preparation platforms; and research use only products.
YTD Price Performance: 3.87%
Average Trading Volume: 287
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $45.11M
For a thorough assessment of ALNOV stock, go to TipRanks’ Stock Analysis page.
